Outputs

The outputs below represent the collective insights of 36 industry leaders brought together for two days of closed-room discussion at the Nucleic Acid Insights Special Interest Group.

Convened to address the field's most pressing questions on the future of CAR-T cell therapy, the group explored the relative promise of in vivo, allogeneic and autologous modalities, solid tumor efficacy, patient access and regulatory alignment, with findings drawn from structured expert discussion and live polling conducted across both sessions.

New content will be added to this page as outputs are released.

The industry speaks: what is the future of CAR-T cell therapy?

CAR-T cell therapy enters its next decade with hard-won momentum and unresolved challenges in equal measure. The science is advancing. The system has not yet caught up.

This pressing challenge brought together 38 leading experts from industry and academia for an invitation-only event exploring the field's most urgent priorities — captured across six live polls over 2 days.